Please try another search
Ascendis Pharma A/S reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 266.72 million compared to EUR 51.17 million a year ago. Net loss was EUR 481.45 million compared to EUR 583.19 million a year ago. Basic loss per share from continuing operations was EUR 8.55 compared to EUR 10.4 a year ago. Diluted loss per share from continuing operations was EUR 8.55 compared to EUR 10.4 a year ago.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 95.89 | 137.7 | 48.03 | 47.39 |
Gross Profit | 88.32 | 118.24 | 40.65 | 34.46 |
Operating Income | -49.14 | -36.61 | -134.41 | -140.84 |
Net Income | -131.04 | -86.88 | -162.22 | -121.43 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 802.5 | 825.59 | 873.21 | 823.82 |
Total Liabilities | 1040.68 | 971.28 | 946.65 | 758.98 |
Total Equity | -238.18 | -145.7 | -73.43 | 64.84 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -101.58 | -42.47 | -124.72 | -153.13 |
Cash From Investing Activities | 7.16 | 6.65 | 22.22 | 46.96 |
Cash From Financing Activities | 18.42 | -6.06 | 143.36 | -2.31 |
Net Change in Cash | -71.92 | -49.1 | 47.05 | -107.06 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review